all report title image
  • Published On : Mar 2022
  • Code : CMI4985
  • Industry : Pharmaceutical
  • Pages : 120
  • Formats :

Vasopressin is antidiuretic hormone. It is naturally secreted by the pituitary gland, which acts on the kidneys and blood vessels. Vasopressin can be used to treat diabetes insipidus through different routes of administration such as intravenous injection, intramuscular injection, and others.

Vasopressin is widely available in the U.S. and is expected to fuel the growth of U.S. vasopressin market over the forecast period. Some examples of vasopressin injections available in the U.S. for treatment of diabetes include vasopressin injection (Eagle Pharmaceuticals, Inc.), pitressin injection (JHP Pharmaceuticals, LLC), and others.

U.S. Vasopressin Market - Impact of the Coronavirus (COVID-19) Pandemic

The supply chain of vasopressin has been hampered to a certain extend in the U.S., owing to global lockdowns and transportation limitations during the COVID-19 pandemic. The COVID-19 pandemic has impacted the U.S. economy and in turn, the U.S. vasopressin market. Quarantines, traveling constraints, and social distancing measures are likely to lead to a steep decline in the business and consumer spending.

However, key companies operating in the market are focusing on initiatives to enhance availability vasopressin for treatment of various diseases during COVID-9 pandemic which is expected to drive market growth over the forecast period.

For instance, in April 2020, Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, announced an initiative to increase availability of Vaprisol (conivaptan hydrochloride) injection for treating hyponatremia, associated with critical care patients during the COVID-19 pandemic. Moreover, Vaprisol is an U.S. FDA approved treatment for hyponatremia, a potentially life-threatening condition that can often afflict patients in the Intensive Care Unit.

The U.S. vasopressin market is estimated to be valued at US$ 894.6 Mn in 2021, and is expected to exhibit a CAGR of 14.7% over the forecast period (2021-2028).

Figure 1: U.S. Vasopressin Market Share (%) Analysis, By Type, 2021

U.S. Vasopressin  | Coherent Market Insights

Increasing regulatory approvals of vasopressin is the major factor that is expected to drive growth of the U.S. vasopressin market over the forecast period.

Increasing regulatory approvals of vasopressin in the U.S. is expected to be the major factor driving the growth of U.S. vasopressin market over the forecast period. For instance, in December 2021, Eagle Pharmaceuticals, Inc., a U.S.-based pharmaceutical company, announced that the U.S. Food and Drug Administration approved the company’s abbreviated new drug application ‘ANDA’ for vasopressin.

CMI table icon

U.S. Vasopressin Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 894.6 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 14.7% 2028 Value Projection: US$ 2,329.9 Mn
Geographies covered:
  • North America: U.S.
Segments covered:
  • By Type: Intravenous Injection, Intramuscular Injection, Subcutaneous Injection, Others
  • By Application: Anti-diuretic Hormone Deficiency, Gastrointestinal Bleeding, Vasodilatory Shock, Ventricular Tachycardia, Fibrillation
  • By End User: Hospitals, Dental Clinics, Others 
Companies covered:

Par Pharmaceutical, Pfizer Inc., Eagle Pharmaceuticals, Inc., Astellas Pharma Inc., Cumberland Pharmaceuticals Inc., Dr. Reddy’s Laboratories Ltd., Athenex, Inc., Otsuka Holdings Co., Ltd, and Azevan Pharmaceuticals, Inc.

Growth Drivers:
  • Increasing regulatory approvals of vasopressin
  • High prevalence of chronic diseases and health conditions such as diabetes insipidus, cardiovascular diseases, septic shock, and others
Restraints & Challenges:
  • High cost of therapy services 

High prevalence of chronic diseases and health conditions such as diabetes insipidus, cardiovascular diseases, septic shock, and others is expected to augment the market growth

High prevalence of chronic diseases and health conditions such as diabetes insipidus, cardiovascular diseases, septic shock, and others in the U.S. is expected to be the major factor driving the growth of U.S. vasopressin market over the forecast period, as vasopressin can be used for the treatment of aforementioned health conditions and ailments. For instance, according to an article published by the JAMA Network Open journal in February 2019, on the basis of data collected from January 1, 2017 to March 31, 2018, it is estimated that 52.8% of hospitalized patients in the U.S. had sepsis and it was found to be the immediate cause of death in 34.9% of the hospitalized patients. The same source also estimates that around 1.7 million adults in the U.S. are affected from sepsis each year, which contributes to more than 250,000 deaths each year.

Figure 2: U.S. Vasopressin Market Share (%) Analysis, By Application, 2021

U.S. Vasopressin  | Coherent Market Insights

U.S. Vasopressin Market – Restraints

Complications related to the use of vasopressin such as cardiac arrest, asthma, and others is expected to act as a restraint for the U.S. vasopressin market over the forecast period. For instance, according to an article published by the Journal of International Medical Research in October 2018, if high concentration of vasopressin is administered into a patient, the vasopressin in the blood can induce adverse events such as gastrointestinal ischemia bradycardia, myocardial ischemia, and others. In some severe cases, the high concentration of vasopressin may also lead to myocardial infarction or cardiac arrest.

U.S. Vasopressin Market – Competitive Landscape

Major players operating in the U.S. vasopressin market include Par Pharmaceutical, Pfizer Inc., Eagle Pharmaceuticals, Inc., Astellas Pharma Inc., Cumberland Pharmaceuticals Inc., Dr. Reddy’s Laboratories Ltd., Athenex, Inc., Otsuka Holdings Co., Ltd, and Azevan Pharmaceuticals, Inc.

Vasopressin is a nonapeptide produced in the hypothalamus, exhibits diverse physiological functions related to hemodynamic modulation, diuresis, and behavior. Vasopressin is similar to oxytocin, differing in the third and eight amino acid. Vasopressin is indicated for the treatment of postoperative abdominal distention, abdominal roentgenography, gastrointestinal bleeding, and diabetes insipidus.

Market Dynamics

Vasopressin is effective in management of after-surgery complications such as vasodilatory shock, new-onset atrial fibrillation, and others, and this is expected to drive the growth of U.S. vasopressin market over the forecast period. For instance, according to an article published by the Journal of Cardiothoracic and Vascular Anesthesia in April 2018, use of arginine vasopressin in cardiac surgery patients resulted in less perioperative complications.

Moreover, rapid research is being carried out to discover better alternatives to local anesthetics with long-lasting effects in dental clinics, which is expected to drive the growth of U.S. vasopressin market over the forecast period. For instance, according to an article published by the Odontology journal in January 2021, use of vasopressin supplemented with 2% lidocaine showed extended anesthetic response times of lidocaine. Lidocaine is a local anesthetic, which is commonly used in dental treatment due to its rapid onset of action and high tissue penetration. Moreover, the same source suggests that appropriate concentration of vasopressin to be used in dentistry can be established with further research in this field.

Key features of the study:

  • This report provides an in-depth analysis of S. vasopressin market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2021-2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the U.S. vasopressin market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include Par Pharmaceutical, Pfizer Inc., Eagle Pharmaceuticals, Inc., Astellas Pharma Inc., Cumberland Pharmaceuticals Inc., Dr. Reddy’s Laboratories Ltd., Athenex, Inc., Otsuka Holdings Co., Ltd, and Azevan Pharmaceuticals, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The U.S. vasopressin market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision making through various strategy matrices used in analyzing the U.S. vasopressin market

Detailed Segmentation:

  • U.S. Vasopressin Market, By Type:
    • Intravenous Injection
    • Intramuscular Injection
    • Subcutaneous Injection
    • Others
  • U.S. Vasopressin Market, By Application:
    • Anti-diuretic Hormone Deficiency
    • Gastrointestinal Bleeding
    • Vasodilatory Shock
    • Ventricular Tachycardia
    • Fibrillation
  • U.S. Vasopressin Market, By End User:
    • Hospitals
    • Dental Clinics
    • Others
  • Company Profiles
    • Par Pharmaceutical*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Developments/Updates
      • Strategies
    • Pfizer Inc.
    • Eagle Pharmaceuticals, Inc.
    • Astellas Pharma Inc.
    • Cumberland Pharmaceuticals Inc.
    • Reddy’s Laboratories Ltd.
    • Athenex, Inc.
    • Otsuka Holdings Co., Ltd
    • Azevan Pharmaceuticals, Inc.

 

 “*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The U.S. vasopressin market is expected to exhibit a CAGR of 14.7% during the forecast period (2021-2028).
The market is estimated to be valued at US$ 894.6 Mn in 2021.
The prominent players operating in the market include Par Pharmaceutical, Pfizer Inc., Eagle Pharmaceuticals, Inc., Astellas Pharma Inc., Cumberland Pharmaceuticals Inc., Dr. Reddy’s Laboratories Ltd., Athenex, Inc., Otsuka Holdings Co., Ltd, and Azevan Pharmaceuticals, Inc.
The market is expected to be valued at US$ 2,329.9 Mn in 2028
Increasing regulatory approvals of vasopressin and high prevalence of chronic diseases and health conditions such as diabetes insipidus, cardiovascular diseases, septic shock, and others are some of the driving factors, which are expected to drive growth of the market.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo